Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 16,786 shares at $27.55 ($462K) on 2024-09-17, disclosed to the SEC on 2024-09-18.
Scheduled sale ($462k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.52 | 2,485 | $68K | 14.8% |
| 2 | $27.52 | 2,485 | $68K | 14.8% |
| 3 | $27.55 | 2,037 | $56K | 12.1% |
| 4 | $27.55 | 2,037 | $56K | 12.1% |
| 5 | $27.56 | 3,871 | $107K | 23.1% |
| 6 | $27.56 | 3,871 |
| $107K |
| 23.1% |
| Total | $27.55 avg | 16,786 | $462K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |